Dianne Bosch, Kim J M van der Velden, Irma M Oving, Dirk N J Wyndaele, Leo E Weijs, W Dick van Schelven, Wim J G Oyen, Erik T Te Beek, Addy C M van de Luijtgaarden, Diederik M Somford, James Nagarajah, Rick Hermsen, Niven Mehra, Winald R Gerritsen, Maarten J van der Doelen, Inge M van Oort
Imaging before 223 Ra-dichloride (223 Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease. The purpose of this study was to evaluate if baseline prostate-specific membrane antigen (PSMA) PET/CT (bPSMA) versus CT is associated with outcomes of 223 Ra therapy. Methods: A secondary analysis of the data of a prospective observational study (NCT04995614) was performed. Patients received a maximum of 6 223 Ra cycles and were retrospectively divided into the bPSMA or baseline CT (bCT) groups...
February 29, 2024: Journal of Nuclear Medicine